Senator Rand Paul (R-KY) has introduced the Royalty Transparency Act of 2024, which mandates federal employees to disclose any royalty profits stemming from new technological advancements. The bill passed unanimously in the Senate Homeland Security and Governmental Affairs Committee on Wednesday.
In an interview on Thursday, Senator Paul expressed concerns about the lack of transparency regarding potential financial ties between decision-makers and pharmaceutical companies during the COVID-19 pandemic. He emphasized the importance of knowing whether individuals involved in vaccine approvals or mandates were receiving money from big Pharma, citing the development and distribution of vaccines by companies like Pfizer and Moderna.
If enacted, the legislation would necessitate the disclosure of federal employees' royalty earnings in an online database accessible to the public. Senator Paul proposed that this measure would enable the public to identify any officials who sanctioned drug treatments while also receiving financial compensation from the drug manufacturers.
Historically, federal agencies such as the National Institutes of Health (NIH) have faced criticism for their reluctance to disclose royalty payments to their researchers.
The bill comes in response to a report by government watchdog group OpenTheBooks, which revealed that over 1,800 government scientists received over 27,000 royalty payments from 2009 to 2016, amounting to hundreds of millions of dollars.
Senator Paul emphasized that this is a substantial sum of money for scientists, with some receiving million-dollar paydays from pharmaceutical companies without disclosing it to the public.
